Add like
Add dislike
Add to saved papers

Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy.

AIMS: To identify the angiographic and tomographic prognostic factors of chronic central serous chorioretinopathy (CSC) treated with half-dose photodynamic therapy (PDT).

METHODS: This is a consecutive series of 61 eyes with chronic CSC treated with half-dose PDT from January 1, 2009 to October 31, 2016.

RESULTS: The mean logMAR best-corrected visual acuity (BCVA) improved from 0.47 to 0.31 at 3 months (p < 0.001). From multivariate regression, the final BCVA was significantly associated with the baseline BCVA (p = 0.003), a diffuse hyperfluorescence pattern on indocyanine green angiography (ICGA) (p = 0.024), posttreatment shallow irregular pigment epithelium detachment (PED) (p = 0.022), and disruption of the ellipsoid zone (p = 0.007). A diffuse hyperfluorescence pattern on ICGA was associated with a 77.4 times risk of subretinal fluid persistence after treatment (p = 0.009).

CONCLUSION: A poor baseline BCVA, diffuse hyperfluorescence ICGA pattern, shallow irregular PED, and disruption of the ellipsoid zone indicate poor prognosis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app